Strategic Acquisition Ceva Santé Animale acquired Scout Bio in early 2024, signaling a strong partner fit for scaling pet therapeutics and channeling Scout’s gene therapy capabilities through a larger global distribution and commercial platform.

One-time Therapies Scout Bio focuses on one-time gene therapy approaches for chronic pet conditions, presenting a differentiated value proposition that could attract partners seeking durable cures and long-term client engagement in veterinary medicine.

CKD Anemia Study Active feline CKD-associated anemia study with potential for life-long relief offers a near-term collaboration or co-development opportunity with clinics, contract research partners, or pharmaceutical sponsors seeking validated to-market pipelines.

Investors & Collaboration Support from leading life sciences investors and a university collaboration with UPenn Gene Therapy Program enhances credibility, making Scout an attractive co-development or licensing candidate for biotech and animal health groups.

Global Vet Reach Existing enrollment across U.S. clinics and a global investor-backed framework position Scout to expand distribution, manufacturing, and regulatory pathways, enabling strategic partnerships with national distributors and veterinary networks.